This disentangling of glucagon's role in lipid metabolism is highly important considering the current development of glucagon‐based drugs to treat obesity and MASLD (Coskun et al., 2022; Day et al., 2009; Finan et al., 2015; Henderson et al., 2016; Urva et al., 2022). The gene discussed is GCG; the disease is obesity disorder.